Immunopharmacology and inflammation

A novel PPARα agonist propane-2-sulfonic acid octadec-9-enyl-amide inhibits inflammation in THP-1 cells

Yun Zhao,1, Lu Yan,1, Xiu-Mei Luo,1, Lu Peng,1, Han Guo,1, Zuo Jing,1, Li-Chao Yang,1, Rong Hu,1, Xuan Wang,1, Xue-Feng Huang,2, Yi-Qing Wang2,*, Xin Jin1,***

1 Xiamen Key Laboratory of Chiral Drugs, Medical College, Xiamen University, Xiamen 361000, China
2 Zhongshan Hospital, Xiamen University, Xiamen 361000, China

Article history:
Received 18 December 2015
Received in revised form 14 June 2016
Accepted 15 June 2016
Available online 16 June 2016

Keywords:
Propanoic-2-sulfonic acid octadec-9-enyl-amide
Peroxisome proliferator activated receptor alpha
Proinflammatory cytokines
Adhesion molecules
Atherosclerosis

Abstract

Our group synthesized propane-2-sulfonic acid octadec-9-enyl-amide (N15), a novel peroxisome pro- liferator activated receptor alpha (PPARα) agonist. Because PPARα activation is associated with inflammation control, we hypothesize that N15 may have anti-inflammatory effects. We investigated the effect of N15 on the regulation of inflammation in THP-1 cells stimulated with lipopolysaccharide (LPS). In particular, we assessed the production of chemokines, adhesion molecules and proinflammatory cytokines, three important types of cytokines that are released from monocytes and are involved in the development of atherosclerosis. The results showed that N15 remarkably reduced the mRNA expression of chemokines, such as monocyte chemotactic protein 1 (MCP-1 or CCL2), interleukin-8 (IL-8) and interferon-inducible protein-10 (IP-10 or CXCL10), and proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). N15 also decreased the protein expression of vascular cell adhesion molecule (VCAM) and matrix metalloproteinase (MMP) 2 and 9. The reduction in the expression of cytokine mRNAs observed following N15 treatment was abrogated in THP-1 cells treated with PPARα siRNA, indicating that the anti-inflammatory effects of N15 are dependent on PPARα activation. Toll-like receptor 4 (TLR4)/nuclear factor-κB and signal transducer and activator of transcription 3 (STAT3) inhibition, which are dependent on PPARα activation, were also involved in the mechanism underlying the anti-inflammatory effects of N15. In conclusion, the novel PPARα agonist, N15, exerts notable anti-inflammatory effects, which are mediated via PPARα activation and TLR4/NF-κB and STAT3 inhibition, in LPS-stimulated THP-1 cells. In our study, N15 exhibits promise for the treatment of atherosclerosis.

© 2016 Elsevier B.V. All rights reserved.

1. Introduction

Cardiovascular diseases have represented the main cause of morbidity and mortality in Western societies since the 20th century and are primarily a consequence of atherosclerosis. Atherosclerosis is classified as a chronic inflammatory disease, as the immune response plays a significant role in all phases of the atherosclerotic process (Fernandez, 2008). Immune cells, such as monocytes, macrophages, and T-cells, are crucial in the development of atheroma, as they release pro-inflammatory cytokines, adhesion molecules and chemokines. Therefore, the modulation of the release of these cytokines from these cells may be a useful therapeutic strategy for the treatment of atherosclerosis.

PPARα is of particular importance in alleviating atherosclerosis due to its roles in regulating lipid metabolism and inflammation (Chawla, 2010; Chen et al., 2013; Khera et al., 2015; Varga et al., 2011). Synthetic PPARα agonists, including fibrates, which are used clinically, improve dyslipidemia and prevent the development of atherosclerosis (Pang et al., 2012). However, fibrates (e.g. fenofibrate) are weak PPARα agonists with low potency, and can cause some side effects, such as liver damage (Schafer et al., 2012). The endogenous PPARα agonist, oleoylethanolamide (OEA), may be an effective anti-atherosclerotic agent, and it acts by inhibiting oxidation, inflammation and hyperlipidemia (Chen et al., 2011; Fu et al., 2007). Unfortunately, OEA is vulnerable to enzymatic hydrolysis to oleic acid and ethanolamine and thus is not expected to be orally active (Fu et al., 2008).
Propane-2-sulfonic acid octadec-9-enyl-amide (N15), a novel PPARα agonist that was synthesized in our laboratory, is an analog of OEA. N15 is resistant to enzymatic hydrolysis and retains its potent ability to activate PPARα (Chen et al., 2015). Because OEA and fibrate have anti-inflammatory effects, we hypothesize that N15 will also be able to alleviate inflammation. In order to prove this hypothesis, in this study, we tested the inhibitory effect of N15 on the release of pro-inflammatory cytokines, chemokines and adhesion molecules in monocytes.

2. Materials and methods

2.1. Reagents

Fetal bovine serum (FBS), penicillin and streptomycin were purchased from Gibco BRL (Carlsbad, CA, USA). LPS and fibrate were purchased from Sigma (St. Louis, MO, USA). N15 (purity ≥ 98%) was synthesized in our laboratory (Chen et al., 2015). The siRNA specific for PPARα and negative control siRNA (NC siRNA) were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA).

2.2. Cell culture

The human monocyte cell line, THP-1 (Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China), were cultured in RPMI-1640 (Hyclone, Logan, UT, USA) supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C with 5% CO₂. The cells were subcultured in suspension every 2 days until passage.

2.3. Cell viability assay

The MTS assay was used to evaluate the toxicity of N15 and fibrate on THP-1 cells. Briefly, THP-1 cells were plated at 2 × 10⁵ cells per well in 96-well plates and stimulated with various concentrations of N15 or fibrate for 24 h. Cell viability was measured with a CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (Promega, Fitchburg, WI, USA) according to the manufacturer’s instructions. Absorbance was read at 490 nm on a Microplate Reader (Molecular Devices, Silicon Valley, CA, USA). Viability was calculated according to the following formula: Viability (%) = A490 (sample)/A490 (control) × 100%.

2.4. Quantitative real-time polymerase chain reaction (qPCR)

THP-1 cells were pretreated with varying concentrations of N15 (20, 50, 100 μM) and fibrate (100 μM) or an equivalent volume of DMSO for 1 h before exposure to LPS (1.0 μg/ml) for another 12 h. Total cellular RNA was extracted using TRIzol® (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. cDNA was synthesized using a Reverse Transcription kit (Thermo Fisher, Boston, MA, USA). The primers were designed by Sangon Biotechnology (Shanghai, China), and their sequences are listed in Table 1. qPCR was performed with the 7300 Real Time PCR System (Applied Biosystems, Life Technologies Corporation, CA, USA), with the following cycling program: thermal activation for 30 s at 95 °C and 40 cycles of PCR with melting for 5 s at 95 °C, followed by annealing/extension for 31 s at 60 °C. The expression of TNF-α, IL-1β, IL-6, IL-8, IP-10, MCP-1, PPARα, fatty-acid translocase (FAT/CD36) and uncoupling protein-2 (UCP-2) in individual samples were normalized to the expression of the control gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

2.5. Western blot analyses

THP-1 cells were pretreated with varying concentrations of N15

![Fig. 1. Effects of N15 and fibrate on cell viability. THP-1 cells were treated with or without N15 or fibrate at different concentrations for 24 h. Then, MTS was added and cell viability was evaluated. (A) Effects of N15 on cell viability. (B) Effects of fibrate on cell viability.](image-url)
Fig. 2. Effects of N15 on the mRNA expression of proinflammatory cytokines and chemokines. (A)-(F) THP-1 cells were pretreated with fenofibrate (100 μM) or N15 (20, 50 and 100 μM) for 1 h before stimulation with LPS (1 μg/ml) for 12 h. The effects of N15 on the mRNA expression of IL-6, TNF-α, IL-1β, IL-8, IP-10 and MCP-1 were evaluated using qPCR. The values are expressed as the mean ± S.D. of triplicate assays. ###P < 0.001 vs. control, *P < 0.05, **P < 0.01 and ***P < 0.001 vs. LPS.

Fig. 3. Effects of N15 on the protein levels of VCAM, MMP2 and MMP9. THP-1 cells were pretreated with fenofibrate (100 μM) or N15 (20, 50 and 100 μM) for 1 h before stimulation with LPS (1 μg/ml) for 24 h. The protein levels of VCAM, MMP2 and MMP9 were evaluated using western blotting. (A) The experiments were repeated three times, and similar results were obtained. Representative immunoblots for VCAM are shown. (B) For the quantitation of the proteins of interest, the band intensities of VCAM were converted to arbitrary densitometric units and normalized to the value of GAPDH. (C) Representative immunoblots for MMP2 and MMP9 are shown. (D)-(E) The band intensities of MMP2 and MMP9 were converted to arbitrary densitometric units and were normalized to the value of GAPDH. The values are expressed as the mean ± S.D. of triplicate assays. **P < 0.01 and ***P < 0.001 vs. control, *P < 0.05, **P < 0.01 and ***P < 0.001 vs. LPS.
2.6. Small-interference RNA (siRNA) transfection of PPARα

A siRNA strategy was employed to silence PPARα in THP-1 cells. Briefly, THP-1 cells were seeded onto 12-well or 6-well plates and cultured for 24 h in fresh medium without antibiotics. Then, the cells were transfected with PPARα siRNA or NC siRNA (negative control) for 24 h using Lipofectamine™ RNAiMAX reagent (Life Technologies™, USA), according to the manufacturer’s instructions. After transfection, the cells were pretreated with 100 μM N15 for 1 h before stimulation with LPS. Total cellular RNA was extracted, and qPCR performed 12 h after stimulation. Additionally, total cellular protein was extracted 24 h after stimulation, and the samples were analyzed by western blotting. A transfection rate of 60–70% of cells was achieved for all the experiments.

2.7. Immunofluorescence assay

THP-1 cells were attached to glass slides coated with 1-lysine using a cyto-centrifuge (Xiangyi, China). For immunofluorescence analysis, the cells were fixed with ice cold 4% paraformaldehyde in PBS for 15 min at room temperature, washed thrice with PBS, and then incubated with 10% goat serum blocking solution for 120 min at room temperature. After an overnight incubation with the primary antibody (p65 polyclonal antibody diluted 1:100) at 4 °C, the cells were washed thrice with PBS, and incubated with secondary antibody (Alexa Fluor® 594-conjugated goat anti-rabbit antibody, Invitrogen, USA). The slides were protected from light and incubated 60 min at room temperature. The cells were then washed thrice with PBS. The nuclei were stained with DAPI (100 ng/ml, Beyotime Biotechnology, China), and observed under a confocal microscope (Olympus FV1000, Tokyo, Japan).

2.8. Statistical analysis

The results are expressed as the mean ± S.D. Statistical analysis was performed using one-way analysis of variance (ANOVA) for the differences within treatments, followed by Student-Newman-Keuls test for comparisons between two groups (Prism 5 for Windows, GraphPad Software Inc., USA). P < 0.05 was considered to be statistically significant.

3. Results

3.1. Effects of N15 and fenofibrate on cell viability

The cytotoxicity of N15 and fenofibrate was evaluated using the MTS assay. Cell viability was unaffected by either N15 at concentrations between 10 μM and 150 μM or fenofibrate at concentrations between 20 μM and 150 μM for 24 h. These results exclude the potential cytotoxic effects of N15 or fenofibrate (Fig. 1).

3.2. N15 inhibits the mRNA expression of chemokines and
In order to verify the inhibitory effect of N15 on inflammatory responses stimulated by LPS, the mRNA expression of some proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and chemokines, such as IL-8, IP-10, and MCP-1, were evaluated using qPCR. The stimulation of THP-1 cells with LPS markedly increased TNF-α, IL-1β, IL-6, IL-8, IP-10, and MCP-1 mRNA expression. Notably, N15 and fenofibrate attenuated the expression of these mRNAs (Fig. 2). Of interest, when used at the same concentration of 100 μM in LPS-stimulated THP-1 cells, the inhibitory effects of N15 on the chemokines, IL-8, IP-10, and MCP-1, were much better than that of fenofibrate (P < 0.001 for all cytokines).

3.3. N15 inhibits VCAM, MMP-2 and MMP-9 protein production

MCP-1 is not only a chemokine, but is also an adhesion molecule. In addition to MCP-1, VCAM is also an important protein that regulates the adhesion of monocytes. MMP-2 and MMP-9, which are mainly produced from monocytes/macrophages, can degrade extracellular matrix components, such as collagens and elastins, resulting in the destabilization of atherosclerotic plaques (Lijnen, 2002). In order to clarify the effect of N15 on VCAM, MMP-2 and MMP-9 production, their protein levels were evaluated using western blotting.

A remarkable increase in the levels of VCAM, MMP-2 or MMP-9 protein was observed in THP-1 cells stimulated with LPS, and the levels of these proteins were all reduced in a dose-dependent manner following N15 treatment (Fig. 3). Of note, when used at the same concentration of 100 μM, the inhibitory effects of N15 on VCAM, MMP2, and MMP9 were greater than that of fenofibrate (P < 0.001, P < 0.001 and P < 0.01, respectively) in LPS-stimulated THP-1 cells (Fig. 3).

3.4. N15 activates PPARα in LPS-induced THP-1 cells

In our previous study, N15 was shown to promote the transactivation of PPARα in HeLa cells (Chen et al., 2015), but whether it could also activate PPARα in THP-1 cells needs verifying. Our results showed that N15 was able to promote PPARα protein
expression in a dose-dependent manner (Fig. 4A and B). Moreover, the increase in PPARα protein expression induced by N15 was almost twice of that induced by the same concentration (100 μM) of fenofibrate in LPS-stimulated THP-1 cells. The mRNA levels of CD36 and UCP-2 (Fig. 4C and D), which are downstream of PPARα, were also observed for MCP-1, IP-10 and IL-8 (Fig. 5B) and chemokines (Tsai et al., 2014) triggers the production of pro-inflammatory cytokines (Hume et al., 2001) and chemokines (Tsai et al., 2014) via NF-κB activation (Luo et al., 2015). To test whether N15 affected the classical TLR4/NF-κB inflammatory signaling pathway induced by LPS, TLR4 and NF-κB p65 protein levels were measured by western blotting. As shown in Fig. 5A, LPS markedly induced the increase in TLR4 levels and the phosphorylation of p65, and treatment with N15 suppressed the phosphorylation of STAT3, the protein level of p-STAT3 was evaluated using western blotting. As shown in Fig. 6D and E, LPS markedly induced the phosphorylation of STAT3, and treatment with N15 suppressed the phosphorylation of STAT3 in a dose-dependent manner, suggesting that N15 has an inhibitory effect on the TLR4/NF-κB inflammatory signaling pathway induced by LPS. STAT3 tyrosine phosphorylation is critical for monocyte chemotaxis and migration (Jougasaki et al., 2010), as well as for IL-6 and IL-1β production (Samavati et al., 2009) in response to LPS. In order to clarify whether N15 prevents the phosphorylation of STAT3, the protein level of p-STAT3 was evaluated using western blotting. As shown in Fig. 6D and E, LPS markedly induced the phosphorylation of STAT3, and treatment with N15 suppressed the phosphorylation of STAT3 in a dose-dependent manner, demonstrating the possible involvement of STAT3 suppression in the anti-inflammatory effect of N15. However, although fenofibrate exhibited inhibitory effects on TLR4/NF-κB and p-STAT3 protein levels, the effects were not significant and were considerably weaker than that observed when cells were treated with the same concentration (100 μM) of N15 (P < 0.001 in the case of either TLR4, p-p65 or p-STAT3) (Fig. 6). Because PPARα interferes with the nuclear translocation of p65 (Bak et al., 2012), we evaluated whether N15, a PPARα agonist, affected NF-κB pathway by regulating p65 translocation. Our immunofluorescence results showed that LPS stimulation resulted in the nuclear import of p65, while N15 treatment prevented p65 from entering the nucleus (Fig. 7).

Taken together, our results showed that N15 attenuates the TLR4/NF-κB and STAT3 inflammatory signaling pathways in LPS-stimulated THP-1 cells through PPARα activation.

Fig. 6. Effect of N15 on TLR4, p-p65 and p-STAT3 protein levels. THP-1 cells were pretreated with fenofibrate (100 μM) or N15 (20, 50 and 100 μM) for 1 h before stimulation with LPS (1 μg/ml) for 24 h. (A) The experiments were repeated three times, and similar results were obtained. Representative immunoblots for TLR4, p65 and p-p65 are shown. (B)-(C) For the quantitation of the proteins of interest, the band intensities of TLR4 and p-p65 were converted to arbitrary densitometric units and were normalized to the value of GAPDH. (D) Representative immunoblots for STAT3 and p-STAT3 are shown. (E) The band intensities of p-STAT3 were converted to arbitrary densitometric units and were normalized to the value of GAPDH. The values are expressed as the mean ± S.D. of triplicate assays. ***P < 0.001 vs. control, **P < 0.01 and ***P < 0.001 vs. LPS.
4. Discussion

Atherosclerosis is considered a chronic inflammatory disease of the vessel walls (Farhat et al., 2013). Monocyte/macrophages are important players in the inflammatory process of this disease (Zhang et al., 2014), and the activation of the monocyte/macrophages by LPS leads to the increased secretion of several proinflammatory cytokines, such as TNF-\(\alpha\), IL-1\(\beta\), IL-6 and MMPs (Christensen et al., 2015). Persistent production of these proinflammatory cytokines can cause severe vascular destruction and eventually atherosclerosis. MMPs not only contribute to the progression of atherosclerotic plaques due to their proinflammatory effects but also cause plaque destabilization by degrading components of the extracellular matrix. In addition, atherosclerotic inflammation involves the recruitment of monocytes during all phases of the disease. Chemokines, such as MCP-1, IL-8 and IP-10 (Mukaida et al., 1998), and adhesion molecules are instrumental in orchestrating the influx of monocytes to the vascular wall (Zernecke and Weber, 2010).

There is mounting evidence that PPAR\(\alpha\) plays a role in inflammation control, as well as lipid regulation. PPAR\(\alpha\) activators exert their anti-inflammatory activities in different vascular wall cell types, such as monocyte/macrophages, endothelial and smooth muscle cells, in which PPAR\(\alpha\) are expressed (Chinetti et al., 2000).

N15 is a novel PPAR\(\alpha\) agonist that was synthesized in our laboratory. It is an analog of the PPAR\(\alpha\) endogenous ligand, OEA, but is resistant to enzymatic hydrolysis and therefore has more stable chemical properties compared to OEA.

In the present study, we investigated the anti-inflammatory effect of N15 in THP-1 cells in response to LPS, which is commonly used for inducing inflammation (Frede et al., 2006; Tsai et al., 2015). Additionally, we compared the difference between N15 and fenofibrate, the mostly common used PPAR\(\alpha\) agonist in the clinic, with respect to their anti-inflammatory effects and the underlying molecular mechanisms.

Based on our results, we drew four main conclusions.

First, N15 has remarkable inhibitory effects on LPS-induced inflammatory responses in THP-1 cells. Three aspects of the anti-inflammatory effects of N15 were evaluated, the expression of proinflammatory cytokine mRNA, the expression of chemokine mRNA and the expression of VCAM and MMPs protein. N15 notably inhibited the expression of all these inflammatory markers in THP-1 cells stimulated with LPS (Figs. 2 and 3).
Second, PPARα activation was found to be responsible for the anti-inflammatory effect of N15. Because N15 was designed to target the spatial structure of PPARα protein, and its ability to activate PPARα was previously shown in Hela cells (Chen et al., 2011), we hypothesized that its anti-inflammatory effect in THP-1 cells would also be dependent on PPARα activation. The hypothesis was verified in the two following ways: (1) N15 treatment increased PPARα protein levels and PPARα downstream genes in THP-1 cells (Fig. 4); (2) PPARα silencing using siRNA reversed the anti-inflammatory effect of N15 (Fig. 5). Thus, the above evidence demonstrates that the inhibitory effect of N15 on LPS-induced inflammatory responses in THP-1 cells is dependent on PPARα activation.

Third, the inhibition of TLR4/NF-κB and STAT3 is also involved in the mechanism by which N15 exerts its anti-inflammatory effect in THP-1 cells in response to LPS. PPARα activators have been shown to inhibit the activation of inflammatory response genes, such as IL-6, IL-8, TNFα and MMPs, by negatively interfering with the NF-κB and STAT3 signaling pathways (Kikuchi et al., 2002; Roglans et al., 2007). Consistently, our results showed that N15 inhibited TLR4/NF-κB and STAT3 signaling pathways in a PPARα-dependent manner (Figs. 6–8), suggesting the involvement of TLR4/NF-κB and STAT3 inhibition in the anti-inflammatory effect of N15.

Finally, N15 is superior to fenofibrate, a clinically used PPARα agonist, in terms of its ability to inhibit inflammation in LPS-stimulated THP-1 cells. N15 showed some advantages over fenofibrate especially with respect to altering the expression of chemokine mRNAs and VCAM and MMPs proteins (Figs. 2 and 3). These advantages might result from the more potent PPARα activation (Fig. 4) and TLR4/NF-κB and STAT3 inhibition caused by N15 treatment, compared with fenofibrate treatment (Fig. 6). In addition, because N15 treatment reduces chemokine mRNA expressions and VCAM protein expression more extensively than fenofibrate, it is possible that, compared to fenofibrate, anti-atherogenic therapy with N15 may decrease monocyte recruitment to the plaque and better increase plaque stability. This requires further investigation in future in vivo studies.

In conclusion, as a novel PPARα agonist, N15 exerts an anti-inflammatory effect that is dependent on PPARα activation and TLR4/NF-κB and STAT3 inhibition and exhibits several advantages over fenofibrate with respect to inflammation control in LPS-stimulated THP-1 cells. Our study suggests that N15 is promising for alleviating atherosclerosis.

**Conflict of interests**

The authors have no conflicts of interest concerning this work.

**Acknowledgments**

This study was supported by grants from the National Science Foundation of China (Grant no. 81373407) and the Natural Science Foundation of Fujian Province (Grant no. 2016J05204).

**References**

macrophages. Molecular 17, 13769–13786.
Chinetti, G., Fruchart, J.C., Staels, B., 2000. Peroxisome proliferator-activated rece-
ptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammm. Res. 49, 497–505.
Fernandez, A.Z., 2008. Peroxisome proliferator-activated receptors in the modula-
Fu, J., Astarita, G., Gaetani, S., Kim, J., Cravatt, B.F., Mackie, K., Piomelli, D., 2007. Food intake regulates oleoylthanolamide formation and degradation in the prox-
Fu, J., Kim, J., Ovessi, F., Astarita, G., Piomelli, D., 2008. Targeted enhancement of oleoylthanolamide production in proximal small intestine induces across-
Jougasaki, M., Ichiki, T., Takenoshita, Y., Setoguchi, M., 2010. Statins suppress in-
terleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus
induced interleukin-8 production by human monocytes through AP-1 and NF-
Mukaida, N., Harada, A., Matsushima, K., 1998. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially in-
volved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 9, 9–23.
Roglans, N., Vila, L., Faire, M., Alegret, M., Sanchez, R.M., Vazquez-Carrera, M., La-
Schafer, H.L., Linz, W., Falk, E., Glien, M., Wieting, W., Hor-
ning, A.W., Rutten, H., 2012. AVE8134, a novel potent PPARalpha agonist, im-
Varga, T., Czimmerer, Z., Nagy, L., 2011. PPARs are a unique set of fatty acid regu-
lators of inflammatory and immune reactions. Cytokine Growth Factor Rev. 9, 9–23.